| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 29 Oct 2026 | SCHEDULE 13G/A |
| 19 Oct 2026 |
8-K: Termination of a Material Definitive Agreement
As previously disclosed, Collegium Pharmaceutical, Inc. (the “Company”) is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH (“Grünenthal”) (as amended, the “Grünenthal License”) which the Company as... |
| 08 Oct 2026 | SCHEDULE 13G/A |
| 30 Sep 2026 | 144 |
| 24 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 |
8-K: Other Events
On August 12, 2026, Collegium Pharmaceutical, Inc. (“Collegium” or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”) with Jefferies LLC to repurchase $50 million of the Company’s co... |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – |
| 05 Aug 2026 | SCHEDULE 13G |
| 31 Jul 2026 | SCHEDULE 13G |
| 17 Jul 2026 | 144 |
| 15 Jul 2026 | 144 |
Loading...